PLCG2 and cancer: Interestingly, it has been shown that DL-BCL cells have a chronically active BCR.32 Moreover, SU-DHL-4 and OCI-LY-1 are reported to have a similar moderate activation of PLCγ2.33 This may indicate that cancer cells may suppress the downstream effects of chronic BCR signaling by either Bcl-2/IP3R interactions to inhibit IP3R signaling or alternatively by switching to the less sensitive IP3R3 isoform.